SCYNEXIS Inc. logo

SCYNEXIS Inc.

SCYX | NASDAQ
Chart Builder DCF Calculator
$4.83
+$0.43 (+9.77%)
Sep 22, 2026, 2:41 PM ET · Market open

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Key Executives

Name Position
David Gonzalez Angulo Chief Executive Officer, President & Director
Ivor Macleod Chief Financial Officer
Scott Sukenick Chief Legal Officer & Corporate Secretary
Daniella Gigante Vice President of Human Resources & Information Technology
SCYNEXIS Inc.
SCYNEXIS Inc. logo
Country United States
IPO Date May 1, 2014
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 18
CEO David Angulo

Contact Details

1 Evertrust Plaza Jersey City, New Jersey 07302-6548 United States

Stock Details

Ticker Symbol SCYX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001178253
CUSIP Number 811292309
ISIN Number US8112923094
SIC Code 2834

© 2026 bestshares.com. All rights reserved.